HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Traditional Chinese Medicine

791.120

+8.5211.09%

Number of Gainers:5

Number of Losers:3

Number of Flat:3

PE:- -

High:794.983

Open:782.836

Low:773.647

Close:782.599

Loading ...

Modern Chinese Medicine Group Plans Acquisition of Hong Kong-Based TCM Manufacturer for Business Expansion

BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman

Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board

THOMSON REUTERS

China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share

Modern Chinese Medicine Group Co. Ltd. Concluded Annual General Meeting

China Traditional Chinese Medicine Holdings Announces Auditor Retirement, Seeks Replacement

Luye Pharma Group Ltd. Conducted Annual General Meeting

BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan Biological

Guangzhou Baiyunshan Pharmaceutical - Capital Increase in Baiyunshan Biological

THOMSON REUTERS

China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024

PuraPharm Corp. Ltd. Conducted Annual General Meeting

Jacobson Pharma Reports Over 40% Increase in FY2025 Profit from Continuing Operations; Profit Attributable to Shareholders Expected to Rise by Over 10%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":791.12,"timestamp":1749197315226,"preClose":782.59894,"halted":0,"volume":197207700,"delay":0,"changeRate":0.010888,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":8.521057,"latestTime":"06-06 16:00:00","open":782.8363,"high":794.9831,"low":773.6471,"amount":611423620,"amplitude":0.027263,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":0.926588,"peRate":14.731709,"turnoverRate":0.013201,"increases":5,"decrements":4,"flats":2,"marketCap":84030869088,"floatMarketCap":55667361632},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":794.9831,"amplitude":0.027263,"preClose":782.59894,"low":773.6471,"pbRate":"0.926588","latestPrice":791.12,"volume":197207700,"delay":0,"open":782.8363,"prevYearClose":739.0471,"prevWeekClose":762.763,"prevMonthClose":762.763,"prevQuarterClose":689.055,"fiveDayClose":762.763,"twentyDayClose":692.536,"sixtyDayClose":701.384,"secType":"PLATE","market":"HK","turnoverRate":0.013201,"peRate":14.731709,"marketCap":84030869088,"floatMarketCap":55667361632,"timestamp":1749197315226,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":5,"down":3,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541079425","title":"Modern Chinese Medicine Group Plans Acquisition of Hong Kong-Based TCM Manufacturer for Business Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2541079425","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541079425?lang=en_us&edition=fundamental","pubTime":"2025-06-05 22:44","pubTimestamp":1749134690,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group Co., Ltd. has announced an update regarding its plans to acquire certain interests in a traditional Chinese medicine  manufacturer located in Hong Kong. The company aims to extend its sales locations to Hong Kong and overseas through this acquisition. The TCM manufacturer in question possesses production lines and sales locations in Hong Kong. The Board of Modern Chinese Medicine Group believes that this strategic move will support the group's international growth objectives. However, it is important to note that only preliminary discussions have taken place with the vendor, and no legally binding agreement has been reached as of yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL4zz4k2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","01643","BK1191"],"gpt_icon":0},{"id":"2541092127","title":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092127","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092127?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:01","pubTimestamp":1749078081,"startTime":"0","endTime":"0","summary":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As ChairmanJune 5 (Reuters) - Tong Ren Tang Technologies Co Ltd 1666.HK:RESIGNATION OF DI SHU BING AS CHAIRMAN OF BOARDFurther company coverage: 1666.HK ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01666","BK1191","BK1606","BK1583","BK1515"],"gpt_icon":0},{"id":"2541929180","title":"Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2541929180","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541929180?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:59","pubTimestamp":1749077956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01666","BK1606","BK1515","BK1583","BK1191"],"gpt_icon":0},{"id":"2540064308","title":"China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2540064308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540064308?lang=en_us&edition=fundamental","pubTime":"2025-06-04 22:13","pubTimestamp":1749046381,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited Announces Special Dividend of HK8.30 Cents and Final Dividend of HK0.35 Cent Per Share. China Traditional Chinese Medicine Holdings Co. Limited announced a final dividend of HK0.35 cent per share and a special dividend of HK8.30 cents per share for the year ended 31 December 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL3xh0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","00570","BK1515"],"gpt_icon":0},{"id":"2539232227","title":"Modern Chinese Medicine Group Co. Ltd. Concluded Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539232227","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539232227?lang=en_us&edition=fundamental","pubTime":"2025-05-30 21:01","pubTimestamp":1748610112,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group Co. Ltd. held its Annual General Meeting on 30 May 2025. At the meeting, several proposals were put forward and approved. The audited consolidated financial statements for the year ended 31 December 2024 were adopted. Additionally, Mr. Leung Tsz Wing and Mr. Wong Chi Kin were re-elected as independent non-executive directors of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine Group Co. Ltd. published the original content used to generate this news brief on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1CTHwK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","01643"],"gpt_icon":0},{"id":"2539237806","title":"China Traditional Chinese Medicine Holdings Announces Auditor Retirement, Seeks Replacement","url":"https://stock-news.laohu8.com/highlight/detail?id=2539237806","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539237806?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:44","pubTimestamp":1748508250,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited announced the retirement of its auditor, Ernst & Young (E&Y), due to regulatory requirements limiting the duration an accounting firm can provide auditing services to central state-owned enterprises and their subsidiaries. As a subsidiary of China National Pharmaceutical Group Co., Ltd., the company is subject to these regulations. E&Y had not yet commenced audit work for the financial year ending December 31, 2025, and the Board confirmed that this change would not significantly impact the annual audit and results release. The company is actively seeking a suitable replacement and will announce the new auditor when appointed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLYLjp0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00570","BK1191","BK1606"],"gpt_icon":0},{"id":"2538474300","title":"Luye Pharma Group Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538474300","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538474300?lang=en_us&edition=fundamental","pubTime":"2025-05-28 22:03","pubTimestamp":1748441006,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. held its Annual General Meeting on 28 May 2025. During the meeting, several proposals were put forward and approved. Mr. HUANG Liming was re-elected as a non-executive Director, and Professor LO Yuk Lam was re-elected as an independent non-executive Director. Ms. XIA Lian was also re-elected as an independent non-executive Director. Additionally, Ernst & Young was re-appointed as the Auditor to hold office until the conclusion of the next annual general meeting of the Company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9WtcnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","02186","BK1191"],"gpt_icon":0},{"id":"2538791422","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan Biological","url":"https://stock-news.laohu8.com/highlight/detail?id=2538791422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538791422?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:21","pubTimestamp":1748427670,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Announces Capital Increase In Baiyunshan BiologicalMay 28  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:CAPITAL INCREASE IN BAIYUNSHAN BIOLOGICALUPON COMPLETION, REGISTERED CAPITAL OF BAIYUNSHAN BIOLOGICAL TO INCREASE TO RMB120.535909 MILLIONFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK1521","00874","BK1191","BK0196","BK0070","BK1197","BK0097","BK0239","BK0183","600332","BK0096","BK0012","BK0028","BK1606","BK1515"],"gpt_icon":0},{"id":"2538424771","title":"Guangzhou Baiyunshan Pharmaceutical - Capital Increase in Baiyunshan Biological","url":"https://stock-news.laohu8.com/highlight/detail?id=2538424771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538424771?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:01","pubTimestamp":1748426495,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nFWN3S00VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600332","00874","BK0188","BK1197","BK0239","BK0196","BK0028","BK0012","BK0070","BK0096","BK0097","BK0183","BK1191","BK1521","BK0175","BK1606","BK1515"],"gpt_icon":0},{"id":"2538463315","title":"China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463315","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538463315?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:17","pubTimestamp":1748344645,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited Announces Final Dividend of HKD 0.0035 Per Share for Year Ended 31 December 2024. China Traditional Chinese Medicine Holdings Co. Limited has announced a final dividend of HKD 0.0035 per share for the financial year ended 31 December 2024. The announcement was updated on 27 May 2025, with shareholders' approval scheduled for 27 June 2025. The ex-dividend date is set for 03 July 2025, with a payment date of 18 July 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL5490b0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1606","00570","BK1191"],"gpt_icon":0},{"id":"2538457932","title":"PuraPharm Corp. Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538457932","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538457932?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:03","pubTimestamp":1748340213,"startTime":"0","endTime":"0","summary":"PuraPharm Corporation Limited held its annual general meeting on 27 May 2025. During the meeting, several proposals were put forward and approved by shareholders. These included the adoption of the audited consolidated financial statements of the company and its subsidiaries, as well as the reports of the directors and the auditor for the year ended 31 December 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PuraPharm Corp. Ltd. published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL81GTNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01498","BK1191","BK1606"],"gpt_icon":0},{"id":"2538085125","title":"Jacobson Pharma Reports Over 40% Increase in FY2025 Profit from Continuing Operations; Profit Attributable to Shareholders Expected to Rise by Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538085125","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538085125?lang=en_us&edition=fundamental","pubTime":"2025-05-26 12:07","pubTimestamp":1748232461,"startTime":"0","endTime":"0","summary":"Jacobson Pharma Reports Over 40% Increase in FY2025 Profit from Continuing Operations; Profit Attributable to Shareholders Expected to Rise by Over 10%. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobson Pharma Corporation Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL8KCfcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02161","02633","BK1606","BK1191"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}